Company intelligence / Profile preview

Still River Fund

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Still River Fund was an early-stage venture capital firm based in Waltham, Massachusetts, that specialized in the life sciences, information technology, and communications sectors. Founded in 1995, the firm primarily targeted Series A and Series B investment opportunities for startups located in the Northeast United States. Its healthcare portfolio included notable companies such as Xanthus Pharmaceuticals, which focused on oncology and autoimmune therapeutics, and Pathogenetix, a developer of rapid bacterial typing systems. The firm was a significant participant in the Boston-area biotech ecosystem during the late 1990s and 2000s but has since ceased active investment operations.

Industry: Investors

Beyond the preview

Go deeper on Still River Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Still River Fund.

Explore the full profile